Literature DB >> 30663686

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity.

Adeline Unterreiner1, Ratiba Touil1, Daniele Anastasi1, Nicolas Dubois1, Satoru Niwa1, Thomas Calzascia1, Frederic Bornancin2.   

Abstract

Besides its function in lymphoid cells, which has been addressed by numerous studies, the paracaspase MALT1 also plays an important role in innate cells downstream of pattern recognition receptors. Best studied are the Dectin-1 and Dectin-2 members of the C-type lectin-like receptor family that induce a SYK- and CARD9-dependent signaling cascade leading to NF-κB activation, in a MALT1-dependent manner. By contrast, Toll-like receptors (TLR), such as TLR-4, propagate NF-κB activation but signal via an MYD88/IRAK-dependent cascade. Nonetheless, whether MALT1 might contribute to TLR-4 signaling has remained unclear. Recent evidence with MLT-827, a potent and selective inhibitor of MALT1 paracaspase activity, indicates that TNF- production downstream of TLR-4 in human myeloid cells is independent of MALT1, as opposed to TNF- production downstream of Dectin-1, which is MALT1 dependent. Here, we addressed the selective involvement of MALT1 in pattern recognition sensing further, using a variety of human and mouse cellular preparations, and stimulation of Dectin-1, MINCLE or TLR-4 pathways. We also provided additional insights by exploring cytokines beyond TNF-, and by comparing MLT-827 to a SYK inhibitor (Cpd11) and to an IKK inhibitor (AFN700). Collectively, the data provided further evidence for the MALT1-dependency of C-type lectin-like receptor -signaling by contrast to TLR-signaling.

Entities:  

Year:  2019        PMID: 30663686     DOI: 10.3791/58439

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  1 in total

1.  Astragalus mongholicus Bunge and Panax notoginseng formula (A&P) improves renal mesangial cell damage in diabetic nephropathy by inhibiting the inflammatory response of infiltrated macrophages.

Authors:  Xiao Lin; Xiao-Qin Lei; Jie-Ke Yang; Jian Jia; Xia Zhong; Rui-Zhi Tan; Li Wang
Journal:  BMC Complement Med Ther       Date:  2022-01-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.